Andrew Marr assesses the changes and impacts of the revised XEVMPD guidance of 5 March 2012

Andrew Marr re-assesses the impact of the revised guidance on XEVMPD issued by EMA on 5 March 2012

XEVMPD data are still required to be submitted to EMA for all authorised medicinal products in Europe by 2 July 2012 but the scope of the data required is reduced.

Click here to view the journal article. Journal Article

This article was published on 15 March 2012 in the on-line version of Scrip Regulatory Affairs.